Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Maxwell Stem

Ophthalmology Camp Hill, PA Medical Doctor

NPI 1093033300 CMS profile 736222

220 Grandview Ave Ste 200, Ste 200, Camp Hill, PA 17011

Open in the dashboard

General payments

$8,097

42 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maxwell Stem of Camp Hill, PA is reported in the CMS Open Payments database as having received $8,097 across 42 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $428 9
2024 General $350 7
2023 General $225 9
2022 General $115 6
2021 General $45 3
2020 General $18 1
2019 General $6,915 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maxwell Stem
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Maxwell Stem were reported at $428. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Maxwell Stem Ophthalmology median Middle half National median
2019 $6,915 $258 $104–$655 $163
2020 $18 $126 $45–$321 $114
2021 $45 $205 $76–$534 $132
2022 $115 $266 $100–$678 $149
2023 $225 $308 $117–$745 $160
2024 $350 $340 $127–$846 $164
2025 $428 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech USA, Inc. $7,030 18 payments
  2. Amgen Inc. $191 1 payment
  3. AbbVie, Inc. $177 7 payments
  4. Regeneron Healthcare Solutions, Inc. $126 6 payments
  5. Allergan Inc. $125 1 payment
  6. Alcon Vision LLC $121 1 payment
  7. Carl Zeiss Meditec USA, Inc. $103 1 payment
  8. Bausch & Lomb Americas Inc. $88 1 payment
  9. Alimera Sciences, Inc. $48 2 payments
  10. Apellis Pharmaceuticals, Inc. $27 1 payment
  11. Other $62 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $5,940 1 payment
  2. Food and Beverage $1,633 39 payments
  3. Travel and Lodging $524 2 payments
Products named General payments · program years 2019–2025
  1. Lucentis $6,800 7 payments
  2. VABYSMO $217 10 payments
  3. TEPEZZA $191 1 payment
  4. OZURDEX Eye Care $153 6 payments
  5. OZURDEX Retina $149 2 payments
  6. Clareon $121 1 payment
  7. CIRRUS HD-OCT $103 1 payment
  8. XIPERE $88 1 payment
  9. EYLEA $80 4 payments
  10. EYLEA HD $47 2 payments
  11. Other $174 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

545

Median for Ophthalmology: 891

Drug cost

$165,696

Median for Ophthalmology: $68,233

Branded share of claims

43.7%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eylea Aflibercept Brand 52 $123,436
Vabysmo Faricimab-Svoa Brand 13 $29,317
Difluprednate Generic 33 $3,535
Prednisolone Acetate Generic 57 $2,763
Ketorolac Tromethamine Generic 63 $1,882
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 67 $1,315
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 106 $1,101
Latanoprost Generic 53 $871
Atropine Sulfate Generic 14 $486
Dorzolamide Hcl Generic 19 $346

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$2,866,223

Of which drugs: $2,424,868

Medicare patients

879

Average age 79

Services billed

36,612

511 women, 368 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Chronic kidney disease 35%
Diabetes 34%
Ischemic heart disease 29%
Atrial fibrillation 23%
Heart failure 20%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 233 1,916 $1,241,859
Injection, faricimab-svoa, 0.1 mg J2777 Office 128 26,160 $716,114
Injection, aflibercept hd, 1 mg J0177 Office 50 1,200 $317,792
Injection, ranibizumab, 0.1 mg J2778 Office 42 694 $86,428

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OZURDEX
  • AbbVie, Inc. $54
$54 — —
Izervay
  • Astellas Pharma US Inc $25
$25 — —
VABYSMO
  • Genentech USA, Inc. $24
$24 13 26,160
ILUVIEN
  • Alimera Sciences, Inc. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

42 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record